Trial Profile
A Phase II Trial of axitinib in Von Hippel-Lindau (VHL) Disease
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 08 Oct 2018
Price :
$35
*
At a glance
- Drugs Axitinib (Primary)
- Indications Von Hippel-Lindau disease
- Focus Therapeutic Use
- 08 Oct 2018 New trial record